Fairfield, Conn — Competitive Technologies, Inc, has announced that researchers at the University of Wisconsin’s (UW) Carbone Cancer Center have begun accepting patients into a new Phase 2 clinical study to evaluate the efficacy of the company’s Calmare Pain Therapy medical device utilizing Scrambler Technology versus a sham procedure in treating painful chemotherapy-induced peripheral neuropathy (CIPN).
The principal investigator for this study is Toby C. Campbell, MD, who is a research physician specializing in medical oncology and palliative care at the UW Carbone Cancer Center.
The study designed by Campbell is a randomized double-blind, sham-controlled clinical trial with a target enrollment of 40 patients that will measure the effectiveness of the devices by recording the change in participants pain as measured by a Visual Analog Scale (VAS) before and after treatment with the Calmare Scrambler MC-5A device or the sham device.
The UW Carbone Cancer Center is recognized throughout the Midwest and the nation as one of the leading innovators in cancer research, quality patient care and active community involvement. The Carbone Cancer Center is the only comprehensive cancer center, as designated by the National Cancer Institute, in Wisconsin.
SOURCE: Competitive Technologies
